Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 3,673 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director directly owned 11,672 shares in the company, valued at $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals International Stock Down 4.9%

Shares of Kiniksa Pharmaceuticals International stock traded down $3.86 during trading on Friday, reaching $74.34. The company’s stock had a trading volume of 1,034,285 shares, compared to its average volume of 737,285. The company has a market cap of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07. The firm’s 50-day moving average is $58.62 and its two-hundred day moving average is $50.96. Kiniksa Pharmaceuticals International, plc has a 52-week low of $29.90 and a 52-week high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. The firm had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.39 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Amundi purchased a new position in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares during the period. Millennium Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Creative Planning bought a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at $358,000. Finally, Quantbot Technologies LP purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on KNSA shares. JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group raised their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Finally, Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $87.38.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.